logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9040714 B1

PDFFull Text
Date of Patent:
May. 26, 2015

Filed:

Apr. 05, 2011

Ire-1α inhibitors

Applicants:

Qingping Zeng, Thousand Oaks, CA (US);

Andras Toro, Oxnard, CA (US);

John Bruce Patterson, Ventura, CA (US);

Warren Stanfield Wade, San Diego, CA (US);

Zoltan Zubovics, Budapest, HU;

Yun Yang, Tianjin, CN;

Zhipeng Wu, Tianjin, CN;

Inventors:

Qingping Zeng, Thousand Oaks, CA (US);

Andras Toro, Oxnard, CA (US);

John Bruce Patterson, Ventura, CA (US);

Warren Stanfield Wade, San Diego, CA (US);

Zoltan Zubovics, Budapest, HU;

Yun Yang, Tianjin, CN;

Zhipeng Wu, Tianjin, CN;

Assignee:

MannKind Corporation, Valenica, CA (US);

Attorney:

Banner & Witcoff, Ltd.

Primary Examiner:

Laura L Stockton

Int. Cl.
CPC ...
C07D 311/16 (2006.01); C07D 405/10 (2006.01); C07D 417/04 (2006.01); A61K 31/366 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/37 (2006.01); A61K 31/381 (2006.01); A61K 31/4025 (2006.01); A61K 31/404 (2006.01); A61K 31/4045 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/4172 (2006.01); A61K 31/4184 (2006.01); A61K 31/423 (2006.01); A61K 31/427 (2006.01); A61K 31/4433 (2006.01); A61K 31/4439 (2006.01); A61K 31/452 (2006.01); A61K 31/453 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 311/20 (2006.01); C07D 311/94 (2006.01); C07D 401/04 (2006.01); C07D 405/04 (2006.01); C07D 409/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/366 (2013.01); C07D 311/16 (2013.01); A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/37 (2013.01); A61K 31/381 (2013.01); A61K 31/4025 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/4172 (2013.01); A61K 31/4184 (2013.01); A61K 31/423 (2013.01); A61K 31/427 (2013.01); A61K 31/4433 (2013.01); A61K 31/4439 (2013.01); A61K 31/452 (2013.01); A61K 31/453 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 311/20 (2013.01); C07D 311/94 (2013.01); C07D 401/04 (2013.01); C07D 405/04 (2013.01); C07D 405/10 (2013.01); C07D 409/04 (2013.01); C07D 417/04 (2013.01);
Abstract

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Find Patent Forward Citations

Loading…